JUNIPER PHARMACEUTICALS INC
JNP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JNP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
—
Lead Asset
crinone (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2018.
Tracking 4 pipeline candidates · 1 clinical trial for JUNIPER PHARMACEUTICALS INC.
Run JUNIPER PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available JUNIPER PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.40
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is JUNIPER PHARMACEUTICALS INC's lead drug candidate?
JUNIPER PHARMACEUTICALS INC's most advanced tracked candidate is crinone (Approved) for progesterone supplementation or replacement as part of an assisted reproductive technology ("ART") treatment for infertile women with progesterone deficiency.
Who is the CEO of JUNIPER PHARMACEUTICALS INC?
Alicia Secor is the chief executive officer of JUNIPER PHARMACEUTICALS INC (JNP).
What therapeutic areas does JUNIPER PHARMACEUTICALS INC focus on?
JUNIPER PHARMACEUTICALS INC develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.